CRISPR Therapeutics AG
CRSPNasdaq
$47.78
↓ -1.6%Jul 17 close · end-of-day
Price
1Y↓ -13.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.6B
Enterprise Value
$2.7B
P/E
—
P/S
1118.5
P/B
2.5
EV/EBITDA
—
PEG
—
FCF Yield
-8.7%
Dividend Yield
—
Revenue (TTM)
$4.1M
Net Income (TTM)
-$568.5M
Free Cash Flow (TTM)
-$401.2M
Gross Margin
—
Operating Margin
-15754.2%
Net Margin
-13856.5%
ROE
-31.3%
ROIC
—
Debt / Equity
0.3
Net Cash
$1.9B
Return 1Y
-13.3%
Company profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.
- CEO
- Samarth Kulkarni
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 460
- Website
- crisprtx.com
Management & directors
- Patel NaimishChief Medical Officer
- Kasinger James R.General Counsel and Secretary
- Kulkarni SamarthChief Executive Officer
- Prasad RajuChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CRSP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.5M↑ +68.6%
Diluted EPS-$1.28↓ -19.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $719,000.00 | $915.0M | $1.2M | $371.2M | $37.3M | $3.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$354.4M | $373.5M | -$673.2M | -$222.5M | -$466.6M | -$664.6M |
| Net income | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| Diluted EPS | -$5.29 | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 |
| Operating cash flow | -$238.4M | $539.0M | -$495.7M | -$260.4M | -$142.8M | -$345.0M |
| Free cash flow | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -49295.5% | 40.8% | -56190.4% | -60.0% | -1250.4% | -18933.6% |
| Net margin | -48520.9% | 41.3% | -54271.7% | -41.4% | -981.5% | -16569.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $517,000.00 | $602,000.00 | $35.7M | $865,000.00 | $892,000.00 | $889,000.00 | $864,000.00 | $1.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$151.3M | -$110.1M | -$64.6M | -$148.4M | -$229.3M | -$132.1M | -$154.8M | -$130.2M |
| Net income | -$126.4M | -$85.9M | -$37.3M | -$136.0M | -$208.5M | -$106.4M | -$130.6M | -$122.9M |
| Diluted EPS | -$1.49 | -$1.01 | -$0.41 | -$1.58 | -$2.40 | -$1.17 | -$1.32 | -$1.28 |
| Operating cash flow | -$95.6M | -$106.9M | -$50.0M | -$53.9M | -$113.9M | -$84.6M | -$92.6M | -$108.9M |
| Free cash flow | -$96.3M | -$107.1M | -$50.3M | -$54.2M | -$114.0M | -$84.7M | -$93.1M | -$109.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -29257.3% | -18294.0% | -181.0% | -17158.8% | -25709.0% | -14854.8% | -17912.5% | -8933.3% |
| Net margin | -24450.3% | -14276.1% | -104.5% | -15722.1% | -23379.9% | -11973.1% | -15117.2% | -8431.5% |
Company news
Jul 18, 2026
Jul 17, 2026
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-29 | Patel Naimish· Chief Medical Officer | Sale | 3,786 | $55.62 | $210,577.32 | filing |
| 2026-05-28 | Patel Naimish· Chief Medical Officer | Option exercise | 10,000 | — | — | filing |
| 2026-03-23 | Kulkarni Samarth· Chief Executive Officer | Sale | 10,020 | $46.78 | $468,735.60 | filing |
| 2026-03-23 | Prasad Raju· Chief Financial Officer | Sale | 3,708 | $46.78 | $173,460.24 | filing |
| 2026-03-23 | KASINGER JAMES R.· General Counsel and Secretary | Sale | 3,182 | $46.78 | $148,853.96 | filing |
| 2026-03-20 | KASINGER JAMES R.· General Counsel and Secretary | Option exercise | 6,250 | — | — | filing |
| 2026-03-20 | Kulkarni Samarth· Chief Executive Officer | Option exercise | 19,687 | — | — | filing |
| 2026-03-20 | Prasad Raju· Chief Financial Officer | Option exercise | 6,250 | — | — | filing |
| 2026-03-16 | Kulkarni Samarth· Chief Executive Officer | Sale | 10,349 | $48.26 | $499,442.74 | filing |
| 2026-03-16 | Prasad Raju· Chief Financial Officer | Sale | 5,848 | $48.26 | $282,224.48 | filing |
| 2026-03-16 | Prasad Raju· Chief Financial Officer | Sale | 4,021 | $48.26 | $194,053.46 | filing |
| 2026-03-16 | KASINGER JAMES R.· General Counsel and Secretary | Sale | 3,450 | $48.26 | $166,497.00 | filing |
| 2026-03-16 | Patel Naimish· Chief Medical Officer | Sale | 3,150 | $48.26 | $152,019.00 | filing |
| 2026-03-16 | Prasad Raju· Chief Financial Officer | Gift | 750 | $0.00 | $0.00 | filing |
| 2026-03-14 | Kulkarni Samarth· Chief Executive Officer | Option exercise | 20,625 | — | — | filing |
| 2026-03-14 | Patel Naimish· Chief Medical Officer | Option exercise | 8,125 | — | — | filing |
| 2026-03-14 | Prasad Raju· Chief Financial Officer | Option exercise | 10,000 | — | — | filing |
| 2026-03-14 | Prasad Raju· Chief Financial Officer | Option exercise | 6,875 | — | — | filing |
| 2026-03-14 | KASINGER JAMES R.· General Counsel and Secretary | Option exercise | 6,875 | — | — | filing |
| 2026-03-11 | Kulkarni Samarth· Chief Executive Officer | Sale | 9,798 | $52.80 | $517,334.40 | filing |
| 2026-03-11 | KASINGER JAMES R.· General Counsel and Secretary | Sale | 2,800 | $52.80 | $147,840.00 | filing |
| 2026-03-10 | KASINGER JAMES R.· General Counsel and Secretary | Option exercise | 5,500 | — | — | filing |
| 2026-03-10 | Kulkarni Samarth· Chief Executive Officer | Option exercise | 19,250 | — | — | filing |
| 2026-02-19 | Kulkarni Samarth· Chief Executive Officer | Sale | 6,967 | $52.58 | $366,324.86 | filing |
| 2026-02-19 | KASINGER JAMES R.· General Counsel and Secretary | Sale | 2,112 | $52.58 | $111,048.96 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.